MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition.
about
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic AgentsPositron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response MonitoringModulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma.Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas.2′-deoxy-2′-[18F] fluoro-D-glucose positron emission tomography, diffusion-weighted magnetic resonance imaging, and choline spectroscopy to predict the activity of cetuximab in tumor xenografts derived from patients with squamous cell carcinoma of t
P2860
MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
MR-detectable metabolic conseq ...... inase kinase (MEK) inhibition.
@en
MR-detectable metabolic consequences of mitogen-activated protein kinase kinase
@nl
type
label
MR-detectable metabolic conseq ...... inase kinase (MEK) inhibition.
@en
MR-detectable metabolic consequences of mitogen-activated protein kinase kinase
@nl
prefLabel
MR-detectable metabolic conseq ...... inase kinase (MEK) inhibition.
@en
MR-detectable metabolic consequences of mitogen-activated protein kinase kinase
@nl
P2093
P2860
P356
P1433
P1476
MR-detectable metabolic conseq ...... inase kinase (MEK) inhibition.
@en
P2093
Alessia Lodi
Sabrina M Ronen
Sarah M Woods
P2860
P304
P356
10.1002/NBM.3109
P577
2014-04-02T00:00:00Z